STERIS (STE)

STERIS remains a high-quality, defensive cash recycler with diversified growth, expanding margins, strong cash conversion, and disciplined capital deployment. Q1 FY'26 results showed broad-based 9% re...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Examine the evolution of Steris' (STE) overseas revenue trends and their effects on Wall Street's forecasts and the stock's prospects.

STERIS plc (NYSE:STE ) Q1 2026 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel A. Carestio - President, CEO & Director Julie Winter - Vice President of Investor Relation...

STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.

Steris (STE) Q1 Revenue Rises 8%

The headline numbers for Steris (STE) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates a...

Steris (STE) came out with quarterly earnings of $2.34 per share, beating the Zacks Consensus Estimate of $2.32 per share. This compares to earnings of $2.03 per share a year ago.

Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Steris (STE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quart...

STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.